A Phase 1b Study of the Safety and Tolerability of Ruxolitinib in Combination With Gemcitabine With or Without Nab-Paclitaxel in Subjects With Advanced Solid Tumors

Trial Profile

A Phase 1b Study of the Safety and Tolerability of Ruxolitinib in Combination With Gemcitabine With or Without Nab-Paclitaxel in Subjects With Advanced Solid Tumors

Discontinued
Phase of Trial: Phase I

Latest Information Update: 17 Apr 2017

At a glance

  • Drugs Ruxolitinib (Primary) ; Gemcitabine; Paclitaxel
  • Indications Pancreatic cancer; Solid tumours
  • Focus Adverse reactions
  • Sponsors Incyte Corporation
  • Most Recent Events

    • 02 Mar 2017 Status changed from active, no longer recruiting to discontinued.
    • 21 Jan 2017 Results of dose finding phase (n=42), presented at the 2017 Gastrointestinal Cancers Symposium.
    • 02 Mar 2016 Planned End Date changed from 1 Mar 2016 to 1 Dec 2016 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top